arrow
返回

Genetic Code Expansion: Inception, Development, Commercialization

delete2021-03-23
delete58
PRE
AI
M
Miglena Manandhar
E
Eugene Chun
F
Floyd E. Romesberg *
DOI:10.1021/jacs.0c11938delete
delete原文链接
delete原文求助
delete分享
delete收藏
摘要

摘要

En 中文
Virtually all natural proteins are built from only 20 amino acids, and while this makes possible all the functions they perform, the ability to encode other amino acids selected for specific purposes promises to enable the discovery and production of proteins with novel functions, including therapeutic proteins with more optimal drug-like properties. The field of genetic code expansion (GCE) has for years enabled the production of such proteins for academic purposes and is now transitioning to commercialization for the production of more optimal protein therapeutics. Focusing on E. coli, we review the history and current state of the field. We also provide a review of the first generation commercialization efforts, the lessons learned, and how those lessons are guiding new efforts. With continued academic and industrial progress, GCE methodologies promise to make possible the routine optimization of proteins for therapeutic use in a way that has only previously been possible with small-molecule therapeutics.
Keyword:
TRANSFER-RNA SYNTHETASE
COLONY-STIMULATING FACTOR
UNNATURAL AMINO-ACIDS
IN-VIVO INCORPORATION
OCCURRING CLINICAL MASTITIS
SUPPRESSOR TRANSFER-RNAS
GROWTH-FACTOR 21
LEPTIN PEG-OB
SEMISYNTHETIC ORGANISM
ESCHERICHIA-COLI

期刊

Journal of the American Chemical Society 封面图
Journal of the American Chemical Society
IF:
15.6
论文数:
20.0W
被引数:
60.2W

机构

暂无机构信息
引用论文

引用论文

err分享
err收藏
Paraproteinemic neuropathy
err2009-09-15
err0
PREAI
errSaša A. Živković; David Lacomis; Suzanne Lentzsch
err分享
err收藏
Example-Based Program Transformation
err2024-09-05
err0
PREAI
errRomain Robbes; Michele Lanza
err分享
err收藏
err分享
err收藏
A position statement on NAFLD/NASH based on the EASL 2009 special conference
err2010-08-01
err870
errOAAI
errRatziu, Vlad; Bellentani, Stefano; Cortez-Pinto, Helena; Day, Chris; Marchesini, Giulio
err分享
err收藏
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
err2003-01-01
err509
errOAAI
errGreen, MD; Koelbl, H; Baselga, J; Galid, A; Guillem, V; Gascon, P; Siena, S; Lalisang, RI; Samonigg, H; Clemens, MR; Zani, V; Liang, BC; Renwick, J; Piccart, MJ
err分享
err收藏
学者 查看更多内容